[Inhibitory effect and mechanism of deoxyschizandrin on NLRP3 inflammasome]

Yao Xue Xue Bao. 2017 Jan;52(1):80-5.
[Article in Chinese]

Abstract

This study was conducted to investigate the inhibitory effect and the molecular mechanism of deoxyschizandrin on the activity of NLRP3 (NOD-like receptor family, pyrin domain containing 3) inflammasome. Bone marrow-derived macrophages were used to study the effects of deoxyschizandrin on inflammasome activation using inflammasome inducers (ATP and nigericin). Cytotoxic effect was evaluated with CCK-8. The expression of IL-1β, caspase-1 in the supernatant and the expression of pro-caspase-1, pro-IL-1β, ASC, NLRP3 in cell was detected by Western blot for the inhibitory effect of deoxyschizandrin (25, 50, 100 and 200 μmol·L(−1)) on the activity of NLRP3 inflammasome. Immunofluorescence was applied to investigate NF-κB (p65) transportation to the nucleus. The results of CCK-8 showed that the optimum concentration of deoxyschizandrin was 6.25–400 μmol·L(−1). Deoxyschizandrin (25, 50, 100, and 200 μmol·L(−1)) could inhibit the activation of NLRP3 inflammasome caused by nigericin and ATP, and inhibit the secretion of IL-1β, which was associated with inhibiting the cleavage of pro-caspase-1. The results of immunofluorescence and Western blot also suggest that the inhibitory activity of deoxyschizandrin on NLRP3 inflammasome was not dependent on NF-κB pathway and protein expression of NLRP3, ASC, pro-caspase-1 and pro-IL-1β mediated by NF-κB. Our results confirmed that deoxyschizandrin could suppress the cleavage of pro-caspase-1 and inhibit the activity of NLRP3 inflammasome at 25–200 μmol·L−1 to reduce the inflammation response.This study was conducted to investigate the inhibitory effect and the molecular mechanism of deoxyschizandrin on the activity of NLRP3 (NOD-like receptor family,pyrin domain containing 3) inflammasome.Bone marrow-derived macrophages were used to study the effects of deoxyschizandrin on inflammasome activation using inflammasome inducers (ATP and nigericin). Cytotoxic effect was evaluated with CCK-8.The expression of IL-1β,caspase-1 in the supernatant and the expression of pro-caspase-1,pro-IL-1β,ASC,NLRP3 in cell was detected by Western blot for the inhibitory effect of deoxyschizandrin (25, 50, 100 and 200 μmol·L(-1)) on the activity of NLRP3 inflammasome. Immunofluorescence was applied to investigate NF-κB (p65) transportation to the nucleus. The results of CCK-8 showed that the optimum concentration of deoxyschizandrin was 6.25-400 μmol·L(-1). Deoxyschizandrin (25, 50, 100,and 200 μmol·L(-1)) could inhibit the activation of NLRP3 inflammasome caused by nigericin and ATP, and inhibit the secretion of IL-1β, which was associated with inhibiting the cleavage of pro-caspase-1.The results of immunofluorescence and Western blot also suggest that the inhibitory activity of deoxyschizandrin on NLRP3 inflammasome was not dependent on NF-κB pathway and protein expression of NLRP3,ASC,pro-caspase-1 and pro-IL-1βmediated by NF-κB. Our results confirmed that deoxyschizandrin could suppress the cleavage of pro-caspase-1 and inhibit the activity of NLRP3 inflammasome at 25-200 μmol·L(-1) to reduce the inflammation response.

MeSH terms

  • Caspase 1 / metabolism
  • Cells, Cultured
  • Cyclooctanes / pharmacology*
  • Humans
  • Inflammasomes / antagonists & inhibitors*
  • Inflammation
  • Interleukin-1beta / metabolism
  • Lignans / pharmacology*
  • Macrophages / drug effects*
  • NLR Family, Pyrin Domain-Containing 3 Protein
  • Polycyclic Compounds / pharmacology*
  • Transcription Factor RelA / metabolism

Substances

  • Cyclooctanes
  • IL1B protein, human
  • Inflammasomes
  • Interleukin-1beta
  • Lignans
  • NLR Family, Pyrin Domain-Containing 3 Protein
  • Polycyclic Compounds
  • RELA protein, human
  • Transcription Factor RelA
  • schizandrin A
  • Caspase 1